Kadcyla

Active Ingredient(s): Ado-Trastuzumab Emtansine
FDA Approved: * February 22, 2013
Pharm Company: * GENENTECH
Category: Cancer

Trastuzumab emtansine,[5][6] sold under the brand name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1.[7][8][9][10] Trastuzumab alone stops growth of cancer cells by binding to the HER2 receptor, whereas trastuzumab emtansine undergoes receptor-mediated internalization into cells, is catabol... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.
1 Discussion

Dosage List

Kadcyla 20 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 50242-087
Labeler:
Genentech, Inc.
Kadcyla 20 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 50242-088
Labeler:
Genentech, Inc.

Related Brands

Drugs with the same active ingredients